Table 1.
Clinicopathological Characteristics of Non-TACE Group Compare with PA-TACE Group Before and After PSM
| Parameters | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| Non-TACE | TACE | P | Non-TACE | TACE | P | |
| (n=48) | (n=61) | (n=31) | (n=31) | |||
| Age(years) | ||||||
| Mean (IQR) | 51.0 [46.0, 56.0] | 49.0 [45.0, 55.0] | 0.564 | 54.0 [48.0, 59.0] | 51.0 [45.5, 59.0] | 0.306 |
| Sex | ||||||
| Female | 6 (12.5%) | 11 (18.0%) | 0.6 | 4 (12.9%) | 3 (9.7%) | 1 |
| Male | 42 (87.5%) | 50 (82.0%) | 27 (87.1%) | 28 (90.3%) | ||
| HBV | ||||||
| No | 13 (27.1%) | 16 (26.2%) | 1 | 9 (29.0%) | 9 (29.0%) | 1 |
| Yes | 35 (72.9%) | 45 (73.8%) | 22 (71.0%) | 22 (71.0%) | ||
| Cirrhosis | ||||||
| No | 6 (12.5%) | 16 (26.2%) | 0.125 | 2 (6.5%) | 7 (22.6%) | 0.149 |
| Yes | 42 (87.5%) | 45 (73.8%) | 29 (93.5%) | 24 (77.4%) | ||
| Tumor Number | ||||||
| Single | 41 (85.4%) | 44 (72.1%) | 0.153 | 27 (87.1%) | 24 (77.4%) | 0.506 |
| Multiple | 7 (14.6%) | 17 (27.9%) | 4 (12.9%) | 7 (22.6%) | ||
| Tumor Size(cm) | ||||||
| ≤5cm | 30 (62.5%) | 16 (26.2%) | <0.001 | 13 (41.9%) | 13 (41.9%) | 1 |
| >5cm | 18 (37.5%) | 45 (73.8%) | 18 (58.1%) | 18 (58.1%) | ||
| Satellite Nodules | ||||||
| No | 24 (50.0%) | 21 (34.4%) | 0.149 | 17 (54.8%) | 10 (32.3%) | 0.124 |
| Yes | 24 (50.0%) | 40 (65.6%) | 14 (45.2%) | 21 (67.7%) | ||
| Differentiation | ||||||
| I+II | 9 (18.8%) | 13 (21.3%) | 0.928 | 3 (9.7%) | 7 (22.6%) | 0.3 |
| III+IV | 39 (81.2%) | 48 (78.7%) | 28 (90.3%) | 24 (77.4%) | ||
| Capsule | ||||||
| No | 26 (54.2%) | 24 (39.3%) | 0.178 | 14 (45.2%) | 10 (32.3%) | 0.434 |
| Yes | 22 (45.8%) | 37 (60.7%) | 17 (54.8%) | 21 (67.7%) | ||
| MVI | ||||||
| No | 9 (18.8%) | 11 (18.0%) | 1 | 5 (16.1%) | 5 (16.1%) | 1 |
| Yes | 39 (81.2%) | 50 (82.0%) | 26 (83.9%) | 26 (83.9%) | ||
| MaVI | ||||||
| No | 41 (85.4%) | 41 (67.2%) | 0.0498 | 24 (77.4%) | 24 (77.4%) | 1 |
| Yes | 7 (14.6%) | 20 (32.8%) | 7 (22.6%) | 7 (22.6%) | ||
| Satoh | ||||||
| I | 26 (54.2%) | 30 (49.2%) | 0.746 | 16 (51.6%) | 15 (48.4%) | 1 |
| II+III | 22 (45.8%) | 31 (50.8%) | 15 (48.4%) | 16 (51.6%) | ||
| AFP(ng/mL) | ||||||
| ≤400 | 24 (50.0%) | 29 (47.5%) | 0.951 | 10 (32.3%) | 17 (54.8%) | 0.124 |
| >400 | 24 (50.0%) | 32 (52.5%) | 21 (67.7%) | 14 (45.2%) | ||
| TBIL(umol/L) | ||||||
| ≤34.2 | 31 (64.6%) | 40 (65.6%) | 1 | 22 (71.0%) | 21 (67.7%) | 1 |
| >34.2 | 17 (35.4%) | 21 (34.4%) | 9 (29.0%) | 10 (32.3%) | ||
| ALP(U/L) | ||||||
| ≤150 | 22 (45.8%) | 23 (37.7%) | 0.509 | 14 (45.2%) | 14 (45.2%) | 1 |
| >150 | 26 (54.2%) | 38 (62.3%) | 17 (54.8%) | 17 (54.8%) | ||
| GGT(U/L) | ||||||
| ≤150 | 11 (22.9%) | 9 (14.8%) | 0.399 | 8 (25.8%) | 4 (12.9%) | 0.335 |
| >150 | 37 (77.1%) | 52 (85.2%) | 23 (74.2%) | 27 (87.1%) | ||
| PALB(mg/L) | ||||||
| ≤170 | 17 (35.4%) | 20 (32.8%) | 0.933 | 11 (35.5%) | 11 (35.5%) | 1 |
| >170 | 31 (64.6%) | 41 (67.2%) | 20 (64.5%) | 20 (64.5%) | ||
| PLT(×10^9/L) | ||||||
| <100 | 4 (8.3%) | 4 (6.6%) | 1 | 2 (6.5%) | 3 (9.7%) | 1 |
| ≥100 | 44 (91.7%) | 57 (93.4%) | 29 (93.5%) | 28 (90.3%) | ||
| PT(s) | ||||||
| ≤13 | 28 (58.3%) | 41 (67.2%) | 0.45 | 16 (51.6%) | 20 (64.5%) | 0.44 |
| >13 | 20 (41.7%) | 20 (32.8%) | 15 (48.4%) | 11 (35.5%) | ||
| Child-Pugh | ||||||
| A | 43 (89.6%) | 55 (90.2%) | 1 | 29 (93.5%) | 27 (87.1%) | 0.668 |
| B | 5 (10.4%) | 6 (9.8%) | 2 (6.5%) | 4 (12.9%) | ||
| FIB-4 | ||||||
| ≤3.25 | 27 (56.2%) | 38 (62.3%) | 0.659 | 15 (48.4%) | 16 (51.6%) | 1 |
| >3.25 | 21 (43.8%) | 23 (37.7%) | 16 (51.6%) | 15 (48.4%) | ||
Note: The bold text means P<0.05.
Abbreviations: AFP, alpha-fetoprotein; ALP, alkaline phosphatase; FIB-4, Fibrosis-4 index; GGT, gamma-glutamyltransferase; HBV, hepatitis B virus; IQR, interquartile range; MaVI, macrovascular invasion; MVI, microvascular invasion; PA-TACE, postoperative adjuvant transarterial chemoembolization; PALB, prealbumin; PLT, platelet; PSM, propensity-score matching; PT, prothrombin time; TBIL, total bilirubin.